News & Updates

Among type 2 diabetes (T2D) patients on first-generation basal insulins (1BIs), a switch to either glargine or degludec in the real-world setting leads to marked improvements in glucose control without increasing the risk of hypoglycaemic events and weight gain, according to a study. Furthermore, the benefits seem to be comparable between the two second-generation basal insulins (2BIs).

In type 2 diabetes (T2D) patients with obesity, calorie restriction helps correct several cardiovascular (CV) risk factors and glomerular hyperfiltration, with the latter translating into a relative long-term stabilization of kidney function, according to a study.

Women with lower body mass index (BMI) who consume high-energy oral nutritional supplements (ONS) late in the afternoon experience only a partial and short-lived energy intake suppression, which increases their total energy intake but has a harmful effect on measures of insulin sensitivity, results of a study have shown.

Once-weekly injection of semaglutide significantly reduced the 10-year risk of developing type 2 diabetes (T2D) among overweight or obese patients, according to a post hoc analysis of the STEP* 1 and 4 trials presented at ADA 2022.